CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project employs rational drug design to target mutated cancerous PI3Kα proteins with small molecule inhibitors. By selectively inhibiting these mutations, the research aims to reduce side effects and improve cancer treatment outcomes.
The application of rational drug design is proven to be more efficient than the traditional way of drug discovery since it aims to understand the molecular basis of a disease.
The aim of this project is to deactivate the mutated cancerous PI3Kα protein with small molecule inhibitors.
It was recently established that PIK3CA, the gene encoding the catalytic p110α subunit of PI3K, is frequently mutated in human malignancies. 80% of these mutations result in amino acid replacements located in either…
BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
